Skip to main content
. 2021 Jan 26;51(2):193–196. doi: 10.1016/j.neucli.2021.01.003

Table 1.

Clinical characteristics of patients in the whole population and according to the presence (FESC <60 μS) or absence of sudomotor dysfunction (FESC ≥60 μS).

Parameters Whole population (n = 50) FESC < 60 µS (n = 13) FESC ≥ 60 µS (n = 37) p
Age (years) 40.6 ± 13.3 53.5 ± 12.5 36.0 ± 10.3 0.0001
BMI (kg/m2) 25.8 ± 3.6 24.9 ± 2.8 26.1 ± 3.8 0.29
Female n, % 16 (32) 5 (38) 11 (30) 0.56
SBP (mm Hg) 122.6 ± 7.8 123.5 ± 8.1 122.2 ± 7.8 0.60
DBP (mm Hg) 78.7 ± 5.4 78.7 ± 4.4 78.7 ± 5.7 0.96
Heart rate (bpm) 87.7 ± 13.2 96.2 ± 12.7 84.8 ± 12.2 0.0061
HESC (µS) 71.2 ± 13.2 58.2 ± 16.8 75.7 ± 7.9 0.0001
Treated at home n, % 16 (32) 8 (62) 8 (22) 0.008
Treated in hospital n, % 34 (68) 5 (38) 29 (78)
Antiviral treatment n % 30 (60) 13 (100) 17 (46) 0.0006
Remdesivir n, % 6 (12) 4 (67) & 2 (33) & 0.01
Other antiviral n, % 24 (48) 9 (69) & 15 (41) & 0.07
At least one motor symptom (48) 24 (92) 12 (32) 12 0.0002
At least one sensory symptom (78) 39 (100) 13 (70) 26 0.02
At least one autonomic symptom (82) 41 (100) 13 (76) 28 0.04

&: percentages calculated only from patients having received remdesivir or another antiviral treatment.